News
Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM
Three years after turning it down for being too expensive, NICE has backed the use of Pfizer’s Vyndaqel as a treatment for transthyretin amyloidosis with cardiomyopathy (A
